arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Rani Therapeutics Holdings, Inc.

RANI
$0.79 ▲ +0.01 (+0.65%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
24 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
35
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Rani Therapeutics Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $142.2M
Dividend Yield
Revenue Growth 893.0%
Op. Margin -488.2%
ROIC -23.2%
FCF / Share $-0.04
Trailing P/E
Price / Book 5.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

24-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.71M
↑ +893.0%
Net Income Profit after all expenses
$-7.03M
↑ +3.2%
Operating Margin Operating profit as % of sales
-488.2%
↓ -82.1%
FCF / Share Free cash flow per share
$-0.04
↑ +85.2%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Financial Health
62
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 24 quarters